Ficerafusp and Nivolumab for Platinum-Resistant Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (ficerafusp alfa and nivolumab) to treat head and neck squamous cell carcinoma that has come back or worsened after platinum chemotherapy. The drugs work by helping your immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma (a type of cancer) in your head or neck area (mouth, throat, or voice box), and it has grown or returned within 6 months after your last platinum chemotherapy
- Your cancer is not suitable for surgery to remove it, or surgery didn't work
- You are between 18 and 75 years old
- Your overall health and ability to do daily activities is good (ECOG score 0 or 1, meaning you can do most normal activities)
- You have not received any prior immunotherapy drugs (like checkpoint inhibitors or anti-PD-1/PD-L1 drugs) or anti-EGFR antibodies
- You do not have active cancer in your brain or spinal cord, or heart/lung conditions that are not well controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two new drugs (ficerafusp alfa and pembrolizumab) along with focused radiation therapy for newly diagnosed head and neck cancer that hasn't spread widely. The goal is to shrink the cancer before surgery and potentially improve survival.
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
This Phase 2 study tests whether adding medicines given into the tumor (gemcitabine, paclitaxel, and carboplatin) plus nivolumab through a vein can shrink or control head and neck cancer that has come back locally. It’s meant for people whose cancer worsened despite standard treatments like surgery, radiation, and platinum chemotherapy (and cetuximab).
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
Hear when a new Squamous Cell Carcinoma of Head and Neck (SCCHN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.